Congressmen Call On GAO To Update Behind-The-Counter Class Investigation

The Government Accountability Office should update its 1995 study of behind-the-counter drug regulatory schemes in o0ther countries to better educate FDA as it considers a third class of drugs in the U.S., members of the House Energy and Commerce Committee say in a Jan. 16 letter to the GAO

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Pink Sheet